What's Happening?
Lysoway Therapeutics has been awarded a $3.4 million grant from The Michael J. Fox Foundation for Parkinson's Research to advance its TMEM175 agonist program. The funding will support preclinical and translational studies of Lysoway's small-molecule TMEM175 agonists,
which aim to improve lysosomal function and cellular resilience in Parkinson's disease. The research will focus on evaluating the therapeutic potential of TMEM175 activation in maintaining lysosomal pH and autophagic capacity. This grant highlights the growing recognition of TMEM175 as a promising target for Parkinson's disease treatment.
Why It's Important?
The grant from The Michael J. Fox Foundation underscores the potential of TMEM175 as a therapeutic target for Parkinson's disease, a neurodegenerative disorder with limited treatment options. By supporting the development of TMEM175 agonists, the foundation aims to advance research that could lead to new therapies capable of modifying disease progression. This funding also highlights the importance of lysosomal ion channels in neurodegenerative diseases and the potential for small-molecule modulators to address key challenges in drug development. The success of this research could pave the way for more effective treatments for Parkinson's disease and other related disorders.
What's Next?
Lysoway Therapeutics will use the grant to conduct mechanistic and efficacy studies across multiple disease-relevant models, with the goal of advancing its TMEM175 agonists towards clinical development. The company plans to establish translational target engagement biomarkers and initiate IND-enabling studies. If successful, this research could lead to the development of new therapies that improve the lives of people living with Parkinson's disease. The findings may also contribute to a better understanding of lysosomal biology and its role in neurodegenerative diseases, potentially informing future therapeutic strategies.
